Aptinyx has quietly paused a phase 2b study for patients with post-traumatic stress disorder.
After a rocky month, the Illinois-based biotech with a focus on brain and nervous system disorders stalled its clinical study of the 150 mg dose of NYX-783, a treatment intended to reduce spontaneous reappearance of fear in patients with PTSD. Going forward, Aptinyx will focus on the second arm of its PTSD treatment study, which looks at a 50mg dose. The lower dose reported positive results in reducing PTSD symptoms following a phase 2 trial in October 2020.
An SEC report, which was only two sentences long, said the phase 2b study of the 50mg dose would continue as planned and be “supported by clinical study sites originally slated for the 150 mg study.”
This is the most recent blow in what has been a disappointing month for Aptinyx. On April 7, the company reported that NYX-2925, its pain reliever for patients with diabetic peripheral neuropathy, had failed to reduce pain in clinical studies and the study snapped to a close.
NYX-783 is one of three drugs in Aptinyx’s current pipeline. The company is also developing NYX-2925, the pain reliever that failed to relieve pain, and NYX-458, which is currently in phase 2 trials to treat cognitive impairment associated with Parkinson’s disease and dementia associated with Lewy bodies.
The company has not released its own public statement with details of the pause.